A single-point mutation (Ala280Val) in the third intracellular loop alters the signalling properties of the human histamine H3 receptor stably expressed in CHO-K1 cells

British Journal of Pharmacology

Volumn 170, Issue 1, 2013, Pages 127-135

  Flores Clemente, Cecilia ^a   Osorio Espinoza, Angélica ^a   Escamilla Sánchez, Juan ^a   Leurs, Rob ^b   Arias, Juan Manuel ^c   Arias Montaño, José Antonio ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b AMSTERDAM INSTITUTE FOR MOLECULES   (Netherlands)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

CHO K1 cells; H3 receptor; histamine; migraine; neuromodulation; orthostatic hypotension

Indexed keywords

ALANINE; CIPROXIFAN; COMPLEMENTARY DNA; CYCLIC AMP; FORSKOLIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HISTAMINE H3 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SULFUR 35; VALINE;

ARTICLE; BINDING AFFINITY; BIOACCUMULATION; CELL MEMBRANE; CELL STIMULATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; INTRACELLULAR SIGNALING; MEMBRANE BINDING; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STABLE EXPRESSION; WILD TYPE;

CHO-K1 CELLS; H3 RECEPTOR; HISTAMINE; MIGRAINE; NEUROMODULATION; ORTHOSTATIC HYPOTENSION;

AMINO ACID SUBSTITUTION; ANIMALS; CELL MEMBRANE; CHO CELLS; COLFORSIN; CRICETULUS; CYCLIC AMP; DNA, COMPLEMENTARY; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; IMIDAZOLES; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; POINT MUTATION; POLYMERASE CHAIN REACTION; RADIOLIGAND ASSAY; RECEPTORS, HISTAMINE H3; SIGNAL TRANSDUCTION;

EID: 84881645133     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12257     Document Type: Article

References (40)

1. Aamodt AH, Stovner LJ, Langhammer A, Hagen K, Zwart JA, (2007). Is headache related to asthma, hay fever, and chronic bronchitis? The Head-HUNT study. Headache 47: 204-212.
2. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. 3 receptor. Trends Pharmacol Sci 28: 350-357.
4. 3 receptor. Biochem Pharmacol 73: 1195-1204.
5. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
6. 3 receptor. Biochem J 355: 279-288.
7. Colosimo C, (2011). Nonmotor presentations of multiple system atrophy. Nat Rev Neurol 7: 295-298.
8. Cutrer FM, (2010). Pathophysiology of migraine. Semin Neurol 30: 120-130.
9. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK, (2007). β-Arrestins and cell signaling. Annu Rev Physiol 69: 483-510.
10. Feuerstein TJ, (2008). Presynaptic receptors for dopamine, histamine, and serotonin. Handb Exp Pharmacol 184: 289-338.
11. 3 receptors expressed in CHO-K1 cells. Inflamm Res 61 (Suppl. 2): S77.
12. 2long dopamine receptors expressed in recombinant cells. Br J Pharmacol 118: 1544-1550.
13. Gutkind JS, (2000). Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. Sci STKE 2000: re1.
14. Guyenet PG, (2006). The sympathetic control of blood pressure. Nat Rev Neurosci 7: 335-346.
15. Haas HL, Sergeeva OA, Selbach O, (2008). Histamine in the nervous system. Physiol Rev 88: 1183-1241.
16. Heatley RV, Denburg JA, Bayer N, Bienenstock J, (1982). Increased plasma histamine levels in migraine patients. Clin Allergy 12: 145-149.
17. Horton RM, Ho SN, Pullen JK, Hunt HD, Cai Z, Pease LR, (1993). Gene splicing by overlap extension. Methods Enzymol 217: 270-279.
18. 3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain. J Med Chem 53: 6445-6456.
19. Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK, (2012). Premotor signs and symptoms of multiple system atrophy. Lancet Neurol 11: 361-368.
20. 3 receptor selective antagonists in clinical trials. J Chem Inf Model 51: 3262-3274.
21. 3 receptors. Mol Pharmacol 63: 378-382.
22. Ku M, Silverman B, Prifti N, Ying W, Persaud Y, Schneider A, (2006). Prevalence of migraine headaches in patients with allergic rhinitis. Ann Allergy Asthma Immunol 97: 226-230.
23. 3 receptor drugs. Nat Rev Drug Discov 4: 107-120.
24. 3 receptors: role of two amino acids in the third transmembrane domain. Br J Pharmacol 131: 1247-1250.
25. 3 receptor. Mol Pharmacol 55: 1101-1107.
26. α-methyl histamine safety and efficacy in migraine prophylaxis: phase III study. Can J Neurol Sci 33: 195-199.
27. Millán-Guerrero RO, Isais-Millán S, Barreto-Vizcaíno S, Rivera-Castaño L, Rios-Madariaga C, (2009). Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study. Eur J Neurol 16: 88-94.
28. 3 receptor as a risk factor for migraine. Arch Med Res 42: 44-47.
29. Oldham WM, Hamm HE, (2007). How do receptors activate G proteins? Adv Protein Chem 74: 67-93.
30. 3 receptors of neurotransmitter release. In:, Shahid M, Khardori N, Kahan RA, Tripathi T, (eds). Biomedical Aspects of Histamine: Current Perspectives. Springer: London, pp. 339-370.
31. 3 receptors modulate glutamatergic transmission in rat globus pallidus. Neuroscience 176: 20-31.
32. 3 receptor and its gene transcripts in rat brain. Neuroscience 114: 173-193.
33. 4 receptor: JNJ7777120 recruits β-arrestin without activating G proteins. Mol Pharmacol 79: 749-757.
34. 3 receptors. Br J Pharmacol 135: 383-392.
35. 3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings. Proc Natl Acad Sci USA 99: 501-506.
36. Tajti J, Párdutz A, Vámos E, Tuka B, Kuris A, Bohár Z, et al. (2011). Migraine is a neuronal disease. J Neural Transm 118: 511-524.
37. 3 receptor. J Pharmacol Exp Ther 301: 451-458.
38. Wess J, (1998). Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther 80: 231-264.
39. 3) and identification of naturally occurring variations. J Neural Transm 109: 443-453.
40. Zamyatnin AA, (1972). Protein volume in solution. Prog Biophys Mol Biol 24: 107-123.